Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study

J. O'Shaughnessy, S. P. Sousa,J. Cruz,L. J. Fallowfield,P. Auvinen,C. Pulido,A. Cvetanovic,S. Wilks,L. Ribeiro, M. Burotto, D. Klingbiel, D. Messeri,A. Alexandrou,P. Trask,J. Fredriksson, L. Stamatovic

Annals of Oncology(2020)

引用 1|浏览35
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要